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Many lymphoma and myeloma patients fail to undergo
ASCT owing to poor mobilization. Identiﬁcation of poor
mobilizers (PMs) would provide a tool for early interven-
tion with new mobilization agents. The Gruppo italiano-
Trapianto di Midollo Osseo working group proposed a
deﬁnition of PMs applicable to clinical trials and clinical
practice. The analytic hierarchy process, a method for
group decision making, was used in setting prioritized
criteria. Lymphoma or myeloma patients were deﬁned
as ‘proven PM’ when: (1) after adequate mobilization
(G-CSF 10 lg/kg if used alone or X5 lg/kg after
chemotherapy) circulating CD34þ cell peak is o20/lL
up to 6 days after mobilization with G-CSF or up to
20 days after chemotherapy and G-CSF or (2) they
yielded o2.0 106 CD34þ cells per kg in p3 apheresis.
Patients were deﬁned as predicted PMs if: (1) they failed
a previous collection attempt (not otherwise speciﬁed); (2)
they previously received extensive radiotherapy or full
courses of therapy affecting SC mobilization; and (3) they
met two of the following criteria: advanced disease (X2
lines of chemotherapy), refractory disease, extensive BM
involvement or cellularity o30% at the time of mobiliza-
tion; age X65 years. This deﬁnition of proven and
predicted PMs should be validated in clinical trials and
common clinical practice.
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Introduction
ASCT of PBSCs is the ﬁrst option for patients with
relapsed lymphoma or multiple myeloma (MM).1–8 Suc-
cessful engraftment correlates with the number of CD34þ
hemopoietic progenitors cells infused;9–12 however, a
proportion of MM or lymphoma patients fail to mobilize
PBSCs and cannot proceed to ASCT.12–18
The deﬁnition of ‘poor’ mobilization varies, owing to the
different parameters set to evaluate the extent of mobiliza-
tion: peak of CD34þ cells in PB, cumulative apheresis
yield or simply percent of candidate patients undergoing
ASCT. Various criteria have been proposed to deﬁne a
successful CD34þ cell mobilization and the adequate
apheresis yield, but these data are difﬁcult to analyse
and compare with each other.10,12,15,19,20 Therefore, a
systematic review of the literature does not provide a clear
deﬁnition of poor mobilization.
Standardization of criteria for diagnosis, prognosis and
response is a major goal of the haematology community
and may facilitate comparison among retrospective and
prospective data. For these reasons, Gruppo italianoTra-
pianto di Midollo Osseo GITMO (Italian Group for Stem
Cell Transplantation) convened a Working Group (WG) to
clarify the deﬁnition of ‘poor mobilizer’ (PM). This is
essential for the assessment of PBSCs’ mobilization in
clinical trials and as a decision criterion for streamlining
mobilization strategies in clinical practice. To develop the
criteria for the deﬁnition of the PM, GITMO-WG adopted
a ﬂexible decision-making method: the analytic hierarchy
process (AHP) was developed to establish priorities and
make the best decision when both the quantitative and
qualitative aspects of a decision needed to be considered
and a poor information base was available.21 AHP is a
multistep process, including four major phases: (1) deﬁning
the goal; (2) decomposing the problem and identifying
critical issues; (3) categorizing/framing the main criteria;
and (4) deﬁning a hierarchy of the criteria. The partici-
pants’ subjective judgment allows them to overcome the
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scarcity or inconsistency of available information on the
problem; ﬁnally, they are forced to quantify their subjective
judgments by pairwise comparisons among the decided
criteria. AHP has been successfully applied to develop
the criteria of refractoriness, resistance or response in
haematology.22,23 The ﬁnal deﬁnition of PM developed by
the GITMO-WG is reported here, along with details with
regard to the AHP method employed for deﬁning criteria
for poor PBSC mobilization.
Methods
A GITMO-WG of seven experts, with speciﬁc expertise
in the ﬁeld of PBSCs’ mobilization, harvest, CD34þ cell
count and ASCT, was selected to develop a standard
deﬁnition of patients with lymphoma or MM failing
to mobilize adequate CD34þ cells to proceed to ASCT
(referred to as PM).
English-language articles were extracted focusing clinical
studies of PBSC mobilization in lymphoma or MM patients
and particularly the studies aimed at deﬁning the adequate
dose of CD34þ cells for ASCT; AHP was used to identify
the values and criteria that deﬁne poor mobilization. The
participants ﬁrst framed the conceptual criteria, and then
the operational criteria: they are qualitative and quantitative,
respectively. For instance, ‘old age’ is a conceptual criterion,
whereas ‘older than 65 years’ is an operational criterion.
Conceptual criteria were selected by the ﬁrst questionnaire,
if there was480% agreement among the participants. Rank
of the core set criteria was assigned through a number from
1 to 9 and the geometric mean of the ranks was calculated.
Framing of operational criteria was obtained through the
second questionnaire and by consensus through the Nominal
Group Technique.24 The participants set the hierarchy of the
operational criteria by pairwise comparison. Each participant
analysed 55 couples of operational criteria and assigned a
relative weight of one criterion with respect to the other one: if
the former criterion was judged to have a higher importance
than the latter, a weight from 1 to 9 was indicated; if the
former criterion was less important than the latter, a weight
from 1/9 to 1 was indicated. Inter-participant standardized
geometric means of the weights for each criterion were
calculated, and subsequently, inter-participant means were
also calculated.
Finally, 36 scenarios were built by the combination of
operational criteria: for each scenario, the participants were
requested to check whether the deﬁnition of ‘predicted
PM’ held. A representative scenario is: ‘The patient is a
predicted PM if he or she is older than 65 years and shows
extensive BM involvement at mobilization’. Each scenario
received approval by each participant. The percent agree-
ment of each scenario was compared with the sum of
weights (obtained by pairwise comparison) of the criteria
composing the scenario itself, and plotted.21
Results
The GITMO-WG agreed that establishing a clear deﬁnition
of PM would help to optimize mobilization and transplant
strategies (Figure 1); this might eventually reduce the need
for: (1) repeated mobilization procedures; (2) SC harvest
from BM; and (3) switch to allogeneic transplantation or
other strategies.
Decomposition of the problem
GITMO-WG deemed that the issue of ‘poor mobilization’
may pertain to three sequential phases:
(i) before the mobilizing treatment, when the mobiliza-
tion procedure is planned;
(ii) during the mobilization procedure; and
(iii) at the completion of the whole PBSCs collection
process.
The criteria supporting a prediction of ‘poor mobiliza-
tion’ in the ﬁrst phase may help one to identify patients at
‘high risk’ of ‘poor mobilization’ (predicted PM) and
cannot be amended because they pertain to a patient’s
history, age or disease status. The criteria supporting a
judgment of ‘poor mobilization’ during the second phase
are markers of the biological capability of the patient to
mobilize SC. They are dynamic and subject to change
while mobilization is ongoing (for example, increase in
the dose of G-CSF or addition of a new drug). The third
phase involves both the host (history and mobilization
ability) and the performance of the apheresis procedure
(apheresis volumes, timing of collections, efﬁciency, and
so on). Keeping in mind an operational deﬁnition of
poor mobilization, GITMO-WG agreed that the criteria for
deﬁning a ‘proven PM’ pertain both to the second and third
phase. However, even if an adequate CD34þ cell peak after
mobilization predicts a successful collection, it cannot be
considered a sufﬁcient condition for a good harvest, as the
latter is dependent on correct timing and performance of
the apheresis procedure.
Framing of criteria
Through the ﬁrst questionnaire, the GITMO-WG analysed
33 candidate conceptual criteria (Table 1); among them two
(nos. 2 and 7) were selected for ‘proven PM’ and ‘proven
poor mobilization’ (PPM) and 10 for ‘predicted PM’ (nos.
14–19 and 21–24); these latter were reduced to eight as
‘disease status’ was split into ‘advanced disease’ and
‘refractory disease’; ‘previous therapy with lenalidomide’
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Figure 1 Goals and reasons of the GITMO-WG project.
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and ‘previous therapy with ﬂudarabine’ were included in
the same category, and the new criteria ‘previous exposure
to other therapies potentially affecting SC mobilization’
include criteria numbers 18,19,22. The reasons for exclud-
ing the remaining criteria included characteristics of the
mobilization strategy (nos. 10–12), redundancy, scarce
clinical application or poor predictive value (that is,
mononuclear cell count). As for the mobilization strategy,
GITMO-WG deemed it necessary to include the optimal
dose of G-CSF in the deﬁnition of PM: G-CSF dose
X10mg/kg if used alone or X5mg/kg after mobilizing
chemotherapy. Through a second questionnaire, GITMO-
WG ranked the 10 conceptual criteria from the core set and
chose among 2–4 operational deﬁnitions for each con-
ceptual criterion (Table 2). Among predicting criteria, a
high rank was assigned to previous extensive radiotherapy
and exposure to drugs known to affect the mobilization
capacity. The operational deﬁnitions of the two criteria for
the proven PM (CD34þ cells peak in PB) and PPM (the
ﬁnal CD34þ cell harvest) were scored and discussed by
Nominal Group Technique.24 As both the criteria con-
curred to the deﬁnition, harmonization of their operational
wording was requested. Moreover, GITMO-WG estab-
lished that the cutoff of X2.0 106 CD34þ cells per kg
harvested must be integrated with a pre-ﬁxed number
of apheresis procedures performed: p3 apheresis days
within a single mobilization attempt, after G-CSF alone
or after chemo-mobilization. Finally, the peak of PB
CD34þ cells was timed according to the mobilization
strategy adopted, as a larger variability in PB CD34þ
kinetics is expected after chemo-mobilization. Operational
criteria for deﬁning ‘predicted PM’ require some adjust-
ments about the age cutoff and BM cellularity; there was
major disagreement with regard to exposure to drugs or
therapies potentially affecting SC mobilization, as a larger
body of evidence supports a detrimental effect of selected
alkylating drugs, that is, melphalan and ﬂudarabine,
whereas fewer reports were published on the detrimental
effect of lenalidomide. Finally, GITMO-WG expressed the
requirement to consider only full-course therapies damaging
SC mobilization, as lower doses or shorter therapies are not
ascertained detrimental factors.
Hierarchy of the operational criteria
The GITMO-WG compared the 10 operational criteria by
pairs and elaborated the relative importance weight of one
criterion to another (Table 2). Pairwise comparison of the
Table 1 Candidate conceptual criteria evaluated in the ﬁrst questionnaire; the core set criteria selected after the ﬁrst questionnaire are
represented in italic bold characters
Conceptual criteria Percentage of
agreement
Main references
1 Harvested CD34+ cells 86 9,11,12,19,20,25–29
2 Harvested CD34+ cells per planned SCT 100
3 No. of planned ASCT 57
4 Overall harvested CD34+ cells after two aphereses 71 20,30,31,28
5 Harvested CD34+ cells at ﬁrst apheresis 57
6 Pre- and post-apheresis CD34+ cell count 57 30–35
7 Absolute number of circulating CD34+ cells per lL 100
8 Overall number of nucleated cells harvested 14 26,35,36
9 Overall number of nucleated cells harvested per planned SCT 14
10 Planned volumes of apheresis 57 30,37–40
11 Chemo-mobilization 71 41–50
12 Mobilizing G-CSF dose 71
13 Diagnosis of underlying disease 71 49,50,51–67
14 Age 100
15 Disease status 100 9,10,12,14,52,56,59,60,68
16 BM involvement 86
17 Pre-mobilization BM cellularity 86
18 No. of previous cytotoxic therapy lines 100 17,18,52–55,59,62,63,69,70
19 Duration of previous chemotherapy 71
20 Interval elapsed since previous chemotherapy 29
21 Previous extensive radiotherapy 100 36,48,52,65,67,68,71,72
22 Previous alkylating therapy 86
23 Previous therapy with lenalidomide 86 73–76
24 Previous therapy with ﬂudarabine 86 77–82
25 Platelet count at ﬁrst apheresis 29 12,14,15,17,30,33–35,38–40,49,56,50,83–86
26 Time to platelet recovery after chemo-mobilization 57
27 Pre-mobilization WBC/Plt count 14
28 Circulating CD34+ cells in steady-state previous PBSC mobilization 14
29 Fold-increase of circulating CD34+ cells per mL with respect to baseline 43 10,12,14,15,19,20,30–35,83,84,87,88
30 Absolute number of circulating CD34+ cells per mL at a predetermined
timing after the start of mobilization
86
31 Kinetics of mobilization of CD34+ cells 43
32 Time to reach the CD34+ cell peak 57
33 Kinetics of mobilization of MNC cells 43
Abbreviation: MNC¼multinucleate cells.
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two criteria deﬁning ‘proven PM’ and PPM (harvested
CD34þ cells and peak CD34þ cells) showed two similar
scores, thus conﬁrming similar ranks. Indeed, GITMO-WG
considered each of the two criteria itself sufﬁcient to sustain
a judgment of ‘predicted PM’, but recognized that a poor
harvest may be caused by technical problems affecting the
extraction efﬁciency and the ﬁnal yield of circulating
CD34þ cells. These problems may consist of delayed or
anticipated timing of apheresis, small volume of processed
blood and any troubles during the procedure that may
prejudice the harvesting, even though the patient achieved a
satisfactory peak of CD34þ cells in PB. Pairwise compa-
rison was particularly important to rank the importance
of the eight criteria for deﬁning ‘predicted PM’. Advanced
disease, refractory disease and previous extensive radio-
therapy were the three criteria that decidedly had a higher
importance. However, GITMO-WG observed that the
criteria were biologically and clinically dependent on the
others and, therefore, covariate.
A third questionnaire was ﬁnally completed including 36
scenarios combining the above eight criteria (Figure 2) and
identiﬁed previous extensive radiotherapy as the most
powerful independent criterion. The scenarios also identi-
ﬁed previous exposure to therapies potentially affecting SC
mobilization as synergic independent factors, whereas
disease status itself was not sufﬁcient to fulﬁl the deﬁnition
of ‘predicted PM’. Therefore, the panel decided to join two
conceptual criteria into a unique exhaustive one, which
included therapies deﬁnitely proven to affect mobilization
and all the other therapies that have been or will be proven
to negatively affect SC mobilization. Finally, GITMO-WG
decided to extend the deﬁnition of predicted ‘PM’ to those
patients with a history of failure, not otherwise speciﬁed,
and listed an additional speciﬁc criterion. On the basis of
the above information, GITMO-WG separated the criteria
for deﬁning ‘predicted PM’ into two categories: major and
minor. The former category included the three most
powerful criteria, which are: previous failed mobilization,
not otherwise speciﬁed, previous extensive radiotherapy
and previous therapies detrimental to SC mobilization. The
second category included: advanced phase disease, refrac-
tory disease, extensive BM involvement, BM cellularity
o30% (before mobilization) and age465 years. Although
one major criterion was sufﬁcient to qualify a patient as
‘predicted PM’, the presence of at least two minor criteria
was requested to qualify a patient as ‘predicted PM’
(Table 3).
Discussion
In this paper, GITMO-WG applied the AHP methods to
select the operational criteria useful to identify the PM in
current medical practice; at least 15% of lymphoma or MM
patients fail to produce the target cell dose of X2 106/
kg CD34þ cells and cannot proceed to ASCT.10,12,15,16,89
Table 2 Relative importance of the selected core set criteria, expressed both as conceptual and by operational deﬁnitions
Conceptual criteria Operational criteria Rank
(1–9)
Pairwise
comparison
Variability
(%)
Harvested CD34+ cells Less than 2.0 106 harvested CD34+ cells per kg per planned
SCT by no more than three aphereses
8.7 0.26 47
Peak of CD34+ cells Peak CD34+ cell count o20/mL on days 4–6 after the start of mobilization
with G-CSF alone or up to 18–20 days after chemotherapy and G-CSF
8.0 0.25 36
Refractory disease 6.0 0.08 74
Advanced disease Advanced disease, that is, at least two previous cytotoxic lines 5.8 0.12 38
Extensive radiotherapy Extensive radiotherapy to marrow bearing tissue 7.2 0.08 54
Previous exposure to ﬂudarabine,
melphalan, lenalidomide
6.6 0.06 47
Previous exposure to other therapies
potentially affecting SC
mobilization
4.8 0.03 67
Extensive BM involvement at
mobilization
5.4 0.04 47
Poor BM cellularity at
mobilization
BM cellularity o30% at mobilization 4.8 0.04 42
Old age Age older than 65 years 5.1 0.02 50
Although the CD34+ cell count reﬂects the biological mobilization ability, whereas the CD34+ cell harvest in a pre-ﬁxed number of apheresis days deﬁnes a
poor mobilization, the terms of poor mobilizer and poor mobilization have been pragmatically considered equivalent. Inter-participant geometric means are
reported. Inter-participants’ variability of pairwise comparison is also reported in the fourth column.
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Figure 2 Scoring of 36 scenarios by sum of pairwise weights of direct
judgment after the third questionnaire evaluation; all the scenarios have
been framed by combining different operational deﬁnitions, generated from
the selected conceptual criteria. The best scored scenarios concurred to the
ﬁnal deﬁnition of proven and predicted poor mobilizer.
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Re-infusion of high doses of CD34þ cells is associated with
fast platelet and neutrophil engraftment, leading to a
signiﬁcant cost sparing25,26,51,90–94 and increased survival
rates.52,95–100 GITMO-WG selected two conceptual criteria
to identify proven PM and/or PPM: (I) peak of CD34þ
cells in PB and (II) harvested CD34þ cells.
The WG agreed about the deﬁnition of PM also for those
patients who did not achieve at least 2.0 106 CD34þ
during 3 apheresis days. Previous reports on the remobi-
lization in this setting show that only a minority of patients
was able to achieve the 2.0 106 CD34þ threshold after a
second mobilization attempt;12,15 in particular, Pusic et al.16
reports that among 269 patients remobilized, only 62 (23%)
yielded X2.0 106 CD34þ .
In the past, the quality of PB harvest has been evaluated
both as CFU-GM and as CD34þ cell content, whereas
limited data suggest a relationship between mononuclear
cell count and CD34þ cell content in mobilized PB.27,32
Despite persistence of controversies about the most reliable
technique for enumerating the CD34þ cell content both in
PB and in the harvest,101–103 GITMO-WG agreed that pre-
apheresis CD34þ cell count in PB is the best predictor of
CD34þ cells in the apheresis products12,16,30,31,33–35,83,84 and
pragmatically considered a peak of CD34þ cells420mL in
PB, as a reliable indicator of a satisfactory mobilization
ability; on the other hand, the strong correlation between
the pre-apheresis CD34þ cell count and the ﬁnal harvest
also indicates that a PPM could be considered a reliable
marker of a proven PM.12,16,30,31,33–35,83,84
The GITMO-WG agreed on 2.0 106 CD34þ cells per
kg as the minimum safe dose for ensuring rapid neutrophil
and platelet recovery both in lymphoma and in MM
patients;10–12,16,25,26,93,94 others suggested a different dose,
such as 2.5 (refs. 9,11,26,28,29,104) or 1.5 106 CD34þ
cells per kg,105 but below 1 106/kg CD34þ cells, a high
risk of delayed platelet recovery has been reported.28
GITMO-WG reviewed the current mobilization strate-
gies as they can inﬂuence the SC mobilization, but cannot
be considered the criteria for the deﬁnition of PM. When
G-CSF alone is used, it is administered at doses ranging
from 10 to 16mg/kg daily;10 higher doses resulted in better
harvest,106–108 not conﬁrmed in subsequent experiences,109
as well the combination of G-CSF plus GM-CSF.110,41,42
After the demonstration of the synergistic effect of CY and
GM-CSF,111 G-CSF followed by chemotherapy has been
reported to mobilize similar number of CD34þ cells;42–44
therefore, as this cytokine has a better safety proﬁle, at
present the mobilization with CY and G-CSF at 5mg/kg is
widespread.44 A randomized study comparing different
doses of G-CSF after chemotherapy did not show
substantial beneﬁt with higher doses.45 The use of disease-
oriented chemo-mobilization in the context of a well-
designed treatment98,112–114 resulted in better harvest
compared with G-CSF alone,10,16 but this did not translate
into a better clinical outcome.46,47 As regards these two
mobilization strategies, GITMO-WG deemed that the same
criteria for identifying the PM should be employed, even if
the different timing of CD34þ cell peaks and the different
doses of G-CSF must be taken in account. GITMO-WG
excluded from deﬁnition of PMs those patients who cannot
reach a CD34þ cell peak X20/mL, but who were equally
able to achieve the target CD34þ cell dose by means ofp3
large-volume aphereses.37
As the identiﬁcation of the ‘predicted PM’ GITMO-WG
deﬁned three major and ﬁve minor criteria, the most
important criteria were as follows: previous cytotoxic
chemotherapy and irradiation. The average decrease
estimated for each cycle of chemotherapy is of 0.2 106
CD34þ cells per kg per apheresis and 1.8 106/kg CD34þ
cells after large-ﬁeld radiotherapy, whereas a local irradia-
tion is not associated with impaired mobilization.36,48,68,69,71
Although underlying disease has been reported as a factor
inﬂuencing mobilization,49,53–56 GITMO-WG deemed that
this is not an independent factor, being inﬂuenced by the
previous treatment and by the disease status. Advanced
disease is often associated with extensive BM involvement.
In addition, in lymphoma patients BM involvement and
platelet count before mobilization are associated with
mobilization failure,9,10,36,57–62 and although it was difﬁcult
to identify a clear age cutoff,63,64 GITMO-WG deemed
that older age is an important factor associated with poor
mobilization.65,50,66
GITMO-WG agreed that the higher percentage of PM is
characterized by either morphological or functional injury
to BM, caused by extensive radiotherapy or/and che-
motherapy, but also by the so-called stem cell poisons.36
Table 3 Final deﬁnitions of proven and predicted poor mobilizer
A patient with MM or lymphoma candidate to ASCT is a:
Proven poor mobilizer If he/she received adequate mobilization (G-CSF doseX10 mg/kg if used alone orX5 mg/kg after chemo) and he/
she shows: peak CD34+ circulating cell count o20/mL on days 4–6 after the start of mobilization with G-CSF
alone or up to 20 days after chemotherapy and G-CSF
OR in the case of proven poor mobilization, that is:o2.0 106 harvested CD34+ cells per kg (that is, minimum
safe dose for each planned ASCT) by p3 aphereses
Predicted poor mobilizer If he/she holds at least one major criterion or at least two minor criteria.
Major criteria:
Failed previous mobilization attempt, not otherwise speciﬁed.
Previous extensive radiotherapy to marrow bearing tissue.
Full courses of previous therapy, including melphalan, ﬂudarabine or other therapies potentially affecting stem
cell mobilization.
Minor criteria:
Advanced phase disease, that is, at least two previous cytotoxic lines
Refractory disease
Extensive BM involvement at mobilization
BM cellularity o30% at mobilization
Age 465 years
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This heterogeneous group of drugs includes purine
analogues, melphalan,67,72 and the list has recently included
thalidomide115 and lenalidomide.73–76 Fludarabine negatively
affects mobilization in patients with CLL;77–80 however, some
authors reported satisfactory collections,81 whereas others
recommend paying attention to the interval from last dose
of ﬂudarabine.82
Among the other factors associated with unsuccessful
mobilization, including PB white cell count, platelet count,
apheresis techniques, interval between last chemotherapy
and mobilization attempt,9,34,38–40,61,69,70,85–88,116,117 the platelet
counts before mobilization seem a reliable indicator of
adequate marrow function, but this factor has not been
considered sufﬁciently powerful like the ones selected as
conceptual criteria.
In conclusion, poor mobilization of SC is a major limitation
to ASCT in lymphoma and MM, and the availability of new
drugs, able to increase the SC mobilization, requires a stringent
deﬁnition of the PM. Several patient- and disease-related
factors have been retrospectively identiﬁed, but never prospec-
tively validated. GITMO-WG recommend that patients
previously failing at least one mobilization attempt should be
candidates for new mobilizing strategies.19,20,118 Excluding this
selected group, the preventive identiﬁcation of PM, by using
the criteria established here, should be validated in a
prospective trial. In the meantime, the GITMO-WG recom-
mend using standard criteria for identifying both the ‘proven
and the predicted PM’ before planning the use of new
mobilizing agents. Recently, two large series of patients with
lymphoma or MM have been retrospectively evaluated deﬁne
PM, according to the standardized criteria: extensive previous
chemotherapy, previous melphalan exposure and a previous
failed mobilization attempt have been identiﬁed as predictive
factors of poor mobilization. Pusic et al.16 reports that 19%
of patients yielding o2 106 CD34þ cells per kg during ﬁve
apheresis after mobilization with G-CSF alone,16 whereas
Wuchter et al.12 identiﬁed 15% of PMs by using the criterion of
a peak concentration 20/mL of CD34þ cells, after chemother-
apy followed by G-CSF.12 The International Myeloma Work-
ing Group also proposed some qualitative predictive risk
factors for poor mobilization, without any ranking.119 The
GITMO-WG worked to deﬁne simple, but stringent opera-
tional criteria for the identiﬁcation/prediction of the PM in the
setting of MM and lymphoma patients. The decision to
separate the criteria for deﬁning ‘predicted PM’ into two
categories (major and minor) could be questionable, but it
keeps the advantage to be easy to use and to update. Recently,
new mobilizing agents, such as plerixafor, proved to be
effective in PM.118,120,121 However, the scientiﬁc community
has not still provided a standard deﬁnition of PM, who may
potentially beneﬁt from this drug; therefore, these criteria could
help the selection of those patients who could beneﬁt from new
mobilizing drugs, waiting for a deﬁnitive validation by a
prospective trial.
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